Christopher J. Logothetis

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (19)

Background Prostate cancer (PCa) bone lesions are bone-forming, which contribute to an immunosuppressive bone-tumor microenvironment (bone-TME). Targeting PCa-induced bone with the radiopharmaceutical Radium-223 (Ra223) is approved for men with bone-metastatic castration-resistant PCa (bmCRPC). We studied the effect of Ra223 on spatial localization of tumor and immune cells in bmCRPC tumor biopsies to gain insights into therapeutic immunomodulation of the bone-TME. Methods Transiliac bone marrow biopsies were performed at baseline and end of treatment (EOT) in 24 patients with bmCRPC treated with Ra223. In three patients with paired specimens containing tumor, multiplex immunofluorescence was performed with antibodies for a tumor cell marker (CK), T-cell markers (CD3, CD4, CD8, FOXP3, and granzyme B), macrophage markers (CD68 [total macrophages] and CD206 [M2-like macrophages]). Results In all three patients, we observed enrichment of CD68 + macrophages, around tumor-induced bone at baseline. CD3 staining revealed T cell depletion where tumor cells formed large sheets but not where tumor cells were scattered. The effects of Ra223 on tumor cells and T cell subsets were heterogeneous. In one patient, tumor cells were reduced, and CD3 + /CD8 + T cells were increased. In a second patient who evidenced osteolytic progression, tumor cells were increased while CD3 + /CD8 + T cells were decreased. In a third patient, there was high number of tumor cells at baseline that modestly decreased and the number of CD3 + /CD8 + T cells modestly increased after Ra223 treatment. Conclusions The changes in tumor cell numbers after Ra223 treatment seemed to be inversely correlated with changes in CD3 + /CD8 + and CD4 + /FoxP3 + cells, but not with other immune cells, in these 3 patients. Further characterization of immune cells in the bone-TME will be required before developing strategies to enhance immunotherapy efficacy in bmCRPC. Clinical trial registration This study does not report the clinical results of a clinical trial, but it does use samples from a completed clinical trial that is registered with clinicaltrials.gov (NCT02135484).

Year:

2026

Treatment decisions in metastatic castration-resistant prostate cancer are mostly guided by clinical variables, but efforts to molecularly monitor the disease remain hampered by challenges in acquiring tumor tissue repeatedly. In this study, we simultaneously profiled the genome copy number and exome in longitudinal plasma circulating tumor DNA (ctDNA) acquired before, during, and upon progression to serial treatments with androgen signaling inhibitors and taxane chemotherapy from 60 patients with metastatic castration-resistant prostate cancer (2–10 samples per patient). The genomic data were used to delineate the clonal substructure and evolutionary dynamics of each patient, and an evolutionary dynamic index was developed to measure the longitudinal changes of the tumor subclones. Treatment with androgen signaling inhibitors resulted in greater subclonal selection and population structure changes than taxane treatment. The subclones that emerged in association with serial therapy resistance harbored recurrent aberrations in previously identified and new candidate genes, with particular enrichment in genes related to PI3K–AKT signaling. These findings indicate that the integration of detailed clinical and genomic data can provide a framework for future unbiased genomic applications for ctDNA in the clinic to enable precision medicine. Significance: Profiling of the genomic copy number changes and mutations in circulating tumor DNA collected longitudinally from prostate cancer patients receiving serial life-prolonging therapies elucidates evolutionary dynamics and identifies emerging resistant subclones.

Year:

2025

S1. Seahorse assays on C4-2B and PC3 cells cultured in 2D. S2. Seahorse assays on C4-2B and PC3 cells cultured in 2D and treated with IACS-10759. S3. Luciferase assay and crystal violet staining are comparable methods for monitoring PCa cells growth. S4. Representative pictures of tumor-free, PC3 tumor-bearing control and PC3 tumor-bearing IACS-10759 treated tibiae.

Year:

2025

Prostate cancer (PCa) bone metastasis (BM) poses a significant clinical challenge due to the heterogeneity of treatment responses and patient outcomes. In this study, we examined the role of Protein Kinase A (PKA) signaling in modulating the expression of osteopontin ( SPP1 /OPN), a protein associated with poor prognosis, within a subset of PCa BM patients. By integrating multi-omics results we identified a novel mechanism in which bone-derived type-I collagen (Col1a1) and fibronectin (Fn1) stimulate SPP1 expression in PCa cells through the activation of PKA signaling. This bone-induced regulation of SPP1 was confirmed both in vitro, using PCa-bone co-culture systems (PC3 or C42B/MC3T3 cell lines), and in vivo, using cell lines’ engraftments and patient-derived xenografts (PDX) grown intrafemorally. Importantly, clinical data from longitudinal patient samples revealed that treatment with enzalutamide, an androgen receptor (AR) inhibitor, led to an increase in PKA signaling and corresponding SPP1 expression in a subpopulation of patients, highlighting the relevance of the PKA/ SPP1 axis in disease progression under AR-targeted therapies. Overall, we underscored the critical role of the bone microenvironment in influencing PCa progression, pointing out to SPP1 /OPN as a biomarker for identifying tumors with active PKA signaling, which could serve to manage resistance to AR-directed treatments.

Year:

2025

Treatment decisions in metastatic castration-resistant prostate cancer are mostly guided by clinical variables, but efforts to molecularly monitor the disease remain hampered by challenges in acquiring tumor tissue repeatedly. In this study, we simultaneously profiled the genome copy number and exome in longitudinal plasma circulating tumor DNA (ctDNA) acquired before, during, and upon progression to serial treatments with androgen signaling inhibitors and taxane chemotherapy from 60 patients with metastatic castration-resistant prostate cancer (2–10 samples per patient). The genomic data were used to delineate the clonal substructure and evolutionary dynamics of each patient, and an evolutionary dynamic index was developed to measure the longitudinal changes of the tumor subclones. Treatment with androgen signaling inhibitors resulted in greater subclonal selection and population structure changes than taxane treatment. The subclones that emerged in association with serial therapy resistance harbored recurrent aberrations in previously identified and new candidate genes, with particular enrichment in genes related to PI3K–AKT signaling. These findings indicate that the integration of detailed clinical and genomic data can provide a framework for future unbiased genomic applications for ctDNA in the clinic to enable precision medicine. Significance: Profiling of the genomic copy number changes and mutations in circulating tumor DNA collected longitudinally from prostate cancer patients receiving serial life-prolonging therapies elucidates evolutionary dynamics and identifies emerging resistant subclones.

Year:

2025

Aberrant metabolic functions play a crucial role in prostate cancer progression and lethality. Currently, limited knowledge is available on subtype-specific metabolic features and their implications for treatment. We therefore investigated the metabolic determinants of the two major subtypes of castration-resistant prostate cancer [androgen receptor–expressing prostate cancer (ARPC) and aggressive variant prostate cancer (AVPC)]. Transcriptomic analyses revealed enrichment of gene sets involved in oxidative phosphorylation (OXPHOS) in ARPC tumor samples compared with AVPC. Unbiased screening of metabolic signaling pathways in patient-derived xenograft models by proteomic analyses further supported an enrichment of OXPHOS in ARPC compared with AVPC, and a skewing toward glycolysis by AVPC. In vitro , ARPC C4–2B cells depended on aerobic respiration, while AVPC PC3 cells relied more heavily on glycolysis, as further confirmed by pharmacologic interference using IACS-10759, a clinical-grade inhibitor of OXPHOS. In vivo studies confirmed IACS-10759′s inhibitory effects in subcutaneous and bone-localized C4–2B tumors, and no effect in subcutaneous PC3 tumors. Unexpectedly, IACS-10759 inhibited PC3 tumor growth in bone, indicating microenvironment-induced metabolic reprogramming. These results suggest that castration-resistant ARPC and AVPC exhibit different metabolic dependencies, which can further undergo metabolic reprogramming in bone. Implications: These vulnerabilities may be exploited with mechanistically novel treatments, such as those targeting OXPHOS alone or possibly in combination with existing therapies. In addition, our findings underscore the impact of the tumor microenvironment in reprogramming prostate cancer metabolism.

Year:

2025

Purpose: To determine the efficacy and safety of risk-adapted combinations of androgen signaling inhibitors and inform disease classifiers for metastatic castration-resistant prostate cancers (mCRPC). Experimental design: In a modular, randomized phase II trial, 192 men were treated with 8 weeks of abiraterone acetate, prednisone and apalutamide (AAPA; Module 1), then allocated to Modules 2 or 3 based on Satisfactory (≥50% PSA decline from baseline and <5 CTC/7.5 mL) versus Unsatisfactory status. Men in the former were randomized to continue AAPA alone (Module 2A) or with ipilimumab (Module 2B). Men in the latter had carboplatin+cabazitaxel added to AAPA (Module 3). Optional baseline biopsies were subject to correlative studies. Results: Median overall survival (from allocation) was 46.4 (95% CI 39.2, 68.2), 41.4 (95% CI 33.3, 49.9) and 18.7 (95% CI 14.3, 26.3) months in Modules 2A (n=64), 2B (n=64) and 3 (n=59) respectively. Toxicities were within expectations. Of 192 eligible patients, 154 (80.2%) underwent pre-treatment metastatic biopsies. The aggressive variant prostate cancer molecular profile (defects in ≥2 of p53, RB1, and PTEN) was associated with Unsatisfactory status. Exploratory analyses suggested SPP1+ and IGFBP2+ macrophages, druggable myeloid cell markers, and germline pathogenic mutations were enriched in the Unsatisfactory group. Conclusions: Adding ipilimumab to AAPA did not improve outcomes in men with androgen responsive mCRPC. Despite the addition of carboplatin+cabazitaxel, men in the Unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups, to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.

Year:

2024

Supplementary Figure S7. Major immune cell types derived from bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (S) and Unsatisfactory (US) groups.

Year:

2024

Supplementary Figure S8. Heatmap showing immune-related Level 1 Reactome and selected Cancer Hallmark pathways in bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (n=27) and Unsatisfactory (n=13) groups.

Year:

2024

Supplementary Figure S11. Proportions of patients with AVPCmDNA and genomic alterations in p53, RB1, and PTEN in each group based on WES of metastatic tumor biopsies from patients in the Satisfactory group (n=37, in red) and in the Unsatisfactory group (n=22, in blue).

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (23)

Taran Gujral

Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Chad Huff

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Louis Pisters

Professor of Urology

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Daniel Frigo

Scientific Director of Research

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nora M. Navone

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Matthew Rettig

Professor

University of California, Los Angeles

UNITED STATES
View details

Sue-Hwa Lin

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andrew Futreal

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Eleonora Dondossola

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Paul Corn

Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

James P. Allison

Professor and Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Daniele Robesti

Vita-Salute San Raffaele University

ITALY
View details

Paul Viscuse

Assistant Professor

University of Virginia

UNITED STATES
View details

Miao Zhang

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Eva Corey

Professor

University of Washington

UNITED STATES
View details

Mark Titus

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ana Aparicio

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sumit Subudhi

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

john Davis

Associate Professor

MD Anderson Cancer Center

UNITED STATES
View details

Neeraj Agarwal

Faculty Member

Dana-Farber Cancer Institute

UNITED STATES
View details

John Ward

Professor

MD Anderson Cancer Center

UNITED STATES
View details

Tanya Dorff

Associate Professor

City Of Hope National Medical Center

UNITED STATES
View details

Wenyi Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details